Novo Nordisk will develop, register, and commercialize UBT251 globally, excluding mainland China, Hong Kong, Macau, and Taiwan. Novo Nordisk pay United Laboratories $200 million upfront, up to $1.8 billion in milestone payments, and tiered royalties on net sales in the licensed territories.

E-nitiateBio and Joincare Pharmaceutical have entered into a licensing agreement for the development and commercialization rights of QY101 inhalation formulation in China.

Alphamab Oncology and 3DMedicines announced that we entered into a license agreement with Glenmark Specialty S.A. a subsidiary of Glenmark Pharmaceuticals Ltd. for the subcutaneous injection PD-L1 antibody drug (R&D code: KN035), pursuant to which, Glenmark was granted exclusive licensing interests in clinical development and commercialization of oncology indications in India, Asia Pacific(except Singapore, Thailand, Malaysia), the Middle East and Africa, Russia, CIS and Latin America.

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases The two companies will develop certain undisclosed molecules of VivaVision for suprachoroidal delivery using Everads’ technology and expertise.

Syncrommune in-licensed YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients from Eucure Biopharma. Eucure has the potential to receive hundreds of millions of US dollars, including an upfront cash payment

KiOmed Pharma licensed out the development and commercial-ization rights for its OA drug KiOmedinevsOne, to Hansoh Pharma for China’s mainland, Macau and Taiwan. KiOmed Pharma is eligible to receive upfront fee and milestone payments of up to €66 million plus double-digit royalties on future product sales.

Propella licensed the develop- ment and commercialization rights for its Ph2 osteoarthritis drug candidate, to ASK Pharma for Greater China. Propella will receive an upfront cash payment and regulatory milestones of several millions USD and royalties on future sales.

ArkBio announced an exclusive license agreement with Commave Therapeutics, an affiliate of Gurnet Point Capital, for the development, manufacture, and commercialization of AZSTARYS in Greater China. ArkBio will provides up to a total of $105.5 million USD in upfront, developmental and sale milestone, as well as tiered royalties on product net sales.

Biosplice licensed the development and commercialization rights for lorecivivint, a novel phase 3 osteoarthritis drug candidate, to Haisco for Greater China. Deal terms included $140 million in aggregate value plus royalties on future sales, including a combination of upfront payment, clinical and commercial milestones.

ArcScan, a medical company focusing on ophthalmology area, received a $11.15 million Preferred Series B investment from Shanghai Haohai Biotech. ArcScan, Inc. would help Haohai further develop their rapidly expanding offering of implantable lenses and, at the same time, provide ArcScan a base from which to expand into the largest ophthalmology market in the world.

SIFI S.p.A. and AffaMed Therapeutics announced they have entered into an agreement to establish a Joint Venture. The Joint Venture would have exclusive rights to SIFI's range of IOLs in Greater China market, including the premium innovative Mini Well®, Mini Well Toric ® and Mini Well Proxa®lines of Extended Depth of Focus ("EDOF") IOL lenses.

ImmuneOncia Therapeutics licensed the development, manufacture, and commercialization rights for IMC-002, a phase 1 CD47 oncology asset, to 3D Medicines for Greater China. ImmuneOncia to receive potentially up to $470.5 million including $8m upfront, and future development and commercial milestone payments, plus tiered royalties on net sales.

CANbridge and Puma reached termination of their 2018 license agreement. Simultaneously Puma agreed with Pierre Fabre to amend the terms of their license agreement, which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX® within Europe and other regions, to also include Greater China.

AUM licensed to Newsoara their current and future pipeline for up to 6 oncology molecules in the Greater China Region. AUM would receive up to $135 million in near-term development, regulatory, and commercial milestones for its current pipeline, and AUM will be eligible to receive up to Double Digit Royalty Payments

Rhizen Pharma licensed the development and commerciali-zation right of Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology to Curon Biopharma for Greater China. License agreement provided Rhizen with up to $149.5 million upfront payment and milestones, plus double-digit royalties on annual net sales of Tenalisib.

Flexion Therapeutics licensed the development and commercialization right of ZILRETTA, the first and only extended-release intra-articular therapy for patients confronting osteoarthritis-related knee pain, to Tainuo for Greater China. Tainuo would pay Flexion an upfront payment of $10 million, and Flexion will also be eligible to receive up to $32.5 million in aggregate milestone payments.

Tarveda licensed the development and commercialization rights for PEN-866, a Phase 1/2a miniature drug conjugate for solid tumors, to SciClone for Greater China. SciClone would pay Tarveda an upfront payment of U.S. $4 million with the right to make a future equity investment in Tarveda of up to U.S. $5 million. Tarveda will be eligible to receive up to $75 million in aggregate milestone payments.

Biomerica signed distribution agreement with Jiangsu Maxhealth for the sale in China of EZ DETECT, a colorectal screening test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. According to the agreement, Maxhealth shall pay up-front pre-payment fee and reach a minimum total purchase amount over 7 years.